Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30781409 | 1.00 | ALPL (1.00) | ALPL | |
| SCHEMBL15211830 | 1.00 | ALPL (1.00) | ALPL | |
| SCHEMBL15211836 | 0.90 | ALPL (1.00) | ALPL | |
| SCHEMBL15212066 | 0.88 | ALPL (1.00) | ALPL | |
| SCHEMBL15211893 | 0.88 | ALPL (0.81) | ALPL | |
| SCHEMBL15212019 | 0.87 | ALPL (1.00) | ALPL | |
| SCHEMBL15212064 | 0.87 | ALPL (1.00) | ALPL | |
| SCHEMBL15211983 | 0.86 | ALPL (1.00) | ALPL | |
| SCHEMBL16376113 | 0.86 | ALPL (0.76) | ALPL | |
| SCHEMBL15212157 | 0.85 | ALPL (1.00) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149374-A1 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-18 | — | — | US | claimed |
| WO-2026102093-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAU-RELATED DISORDERS | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4705488-A1 | AAV CAPSID VARIANTS AND USES THEREOF | Voyager Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025235734-A2 | AAV CAPSID VARIANTS AND USES THEREOF | VOYAGER THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4565597-A2 | COMPOSITIONS AND METHODS FOR CROSSING THE BLOOD BRAIN BARRIER | Voyager Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025100970-A1 | TNAP INHIBITORY COMPOUND AND USE THEREOF | 주식회사 레드엔비아 | 2025-05-15 | — | — | WO | disclosed |
| WO-2024229425-A1 | AAV CAPSID VARIANTS AND USES THEREOF | VOYAGER THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024030976-A2 | COMPOSITIONS AND METHODS FOR CROSSING THE BLOOD BRAIN BARRIER | VOYAGER THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023169327-A1 | CRYSTAL FORM OF PYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 贝达药业股份有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-20230149374-A1 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149374-A1 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS | TNNI3, TNNT2, ACP3 | ALPL 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.